UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

Current Report Pursuant

to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  June 8, 2016

 

 

AGILE THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

 

 

 

 

Registrant’s telephone number, including area code: (609) 683-1880

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 5.07.     Submission of Matters to a Vote of Security Holders.

 

At the 2016 annual meeting of stockholders (the “Annual Meeting”) of Agile Therapeutics, Inc. (the “Company”) held on June 8, 2016, the following proposals were submitted to the stockholders of the Company:

 

Proposal 1:	The election of two directors to serve as Class II directors until the Company’s 2019 annual meeting of stockholders and until their successors are duly elected and qualified.
Proposal 2:	The ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2016.

 

For more information about the foregoing proposals, see the Company’s definitive proxy statement on Schedule 14A filed with the United States Securities and Exchange Commission on April 25, 2016 (the “Proxy Statement”). Of the 28,738,050 shares of the Company’s common stock entitled to vote at the Annual Meeting, 26,909,955 shares, or approximately 93.6%, were represented at the meeting in person or by proxy, constituting a quorum. The number of votes cast for, against or withheld, as well as abstentions and broker non-votes, if applicable, in respect of each such proposal is set forth below:

 

Proposal 1:

Election of Directors.

 

The Company’s stockholders elected the following two directors to serve as Class II directors until the 2019 annual meeting of stockholders and until their successors are duly elected and qualified. The votes regarding the election of the directors were as follows:

 

Director		Votes For		Votes Withheld		Broker Non-Votes
Karen Hong, Ph.D.		21,674,051		1,719,545		3,516,359
William T. McKee		23,157,630		235,966		3,516,359

 

 

Proposal 2:

Ratification of Appointment of Ernst & Young LLP.

 

The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2016. The votes regarding this proposal were as follows:

 

Votes For		Votes Against		Votes Abstaining		Broker Non-Votes
26,881,152		27,550		1,253		—

 

2

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	AGILE THERAPEUTICS, INC.
Date: June 8, 2016	By:	/s/ Alfred Altomari
		Alfred Altomari
		Chief Executive Officer

 

3